We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PLAB:NASDAQPhotronics, Inc. Analysis

Data as of 2026-04-24 - not real-time

$52.27

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Photronics is trading at $52.27, just below its 52‑week high of $52.79 and the calculated resistance level, while the 20‑day SMA of $44.76 sits well under the current price, confirming a strong bullish momentum. The 14‑day RSI of 78.9 indicates the stock is in overbought territory, and recent insider sales by multiple directors add a short‑term cautionary signal. Technical indicators such as a bullish MACD histogram (+0.58) and a clear upward trend support continued price strength, but the high 30‑day volatility of 59% and a beta of 2.83 suggest amplified price swings. Fundamentally, the company posts solid margins (gross 35%, operating 24%) and modest revenue growth of 6.1%, yet the DCF‑derived fair value of $21.6 places the market price over 10% above intrinsic estimates, signaling potential overvaluation. The PE ratio of 22 is well below the industry average of 38, making the stock appear cheap on a relative earnings basis, but the lack of dividend and the elevated risk profile temper enthusiasm. Looking ahead, growing demand for AI‑driven semiconductors could boost Photronics' long‑term prospects, while the current technical overextension and insider selling warrant a measured approach.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI in overbought zone
  • Proximity to resistance at $52.79
  • Recent insider selling activity

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Bullish MACD and sustained uptrend
  • Strong operating margins and cash position
  • Valuation premium relative to DCF fair value

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Secular growth in AI semiconductor demand
  • Moderate revenue growth and solid profitability
  • Industry‑relative earnings multiple advantage

Key Metrics & Analysis

Financial Health

Revenue Growth6.10%
Profit Margin15.83%
P/E Ratio22.3
ROE12.22%
ROA7.31%
Debt/Equity0.00
P/B Ratio2.5
Op. Cash Flow$266.6M
Free Cash Flow$36.5M
Industry P/E38.1

Technical Analysis

TrendBullish
RSI78.9
Support$36.63
Resistance$52.79
MA 20$44.76
MA 50$40.15
MA 200$29.42
MACDBullish
VolumeStable
Fear & Greed Index88.02

Valuation

Fair Value$21.61
Target Price$47.00
Upside/Downside-10.08%
GradeOvervalued
TypeBlend

Risk Assessment

Beta2.83
Volatility59.13%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.